XIENCE V® USA
July 6, 2024HCRI-DAPT
July 6, 2024XIENCE V® USA
July 6, 2024HCRI-DAPT
July 6, 2024XIENCE V® USA
July 6, 2024HCRI-DAPT
July 6, 2024The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI).
Read Study